Other targets are cerebral infarction, deep white matter infarction, perinatal brain disorder, neonatal chronic lung disease (CLD) etc. So far, the company has developed a GCTP-compliant manufacturing method, quality test methods, nonclinical efficacy test methods using prototype formulation, and nonclinical safety tests. Anti-SSEA3 antibody is used as a marker. Clinical trials to administer Muse cell preparations for acute myocardial infarction are planned during FY 2017, and LLSI aims to apply for approval in FY 2020.
LLSI, Lecture at 16th Annual Meeting of the Japanese Society for Regenerative Medicine